Ca absorption is regulated by 1,25(OH)2D, and serum values vary inversely with Ca intake. In sarcoidosis, 1,25(OH)2D is produced by alveolar macrophages in response to y-interferon, and patients may develop hypercalcemia after prolonged exposure to sunlight and increased dermal production of vitamin D3. To determine if increased Ca intake suppresses serum 1,25(OH)2D in normocalcemic patients and to identify those at risk, 17 normal subjects and 11 patients were studied on a metabolic ward for two and one-half days while receiving first 400 and then 1,000 mg/d of Ca. On the low Ca intake, serum angiotensin-converting enzyme (ACE), an index of disease activity, was higher in only three of the patients than in the controls, mean serum 1,25(OH)2D was higher in the patients, and mean serum total Ca, serum Ca ", and urinary Ca were not different in the two groups. On the higher Ca intake, mean urinary Ca increased in both groups, but mean serum 1,25(OH)2D was suppressed only in the normal subjects. Thus, 1,25(OH)2D production is abnormally regulated, indicating that (a) normocalcemic patients with sarcoidosis are at risk for developing abnormal Ca metabolism, and (b) a better index of disease activity is provided by the oral Ca suppression test than by serum ACE. (J. Clin. Invest. 1993. 91:1396-1398
Introduction
Circulating 1,25 (OH )2D is the major determinant ofintestinal absorption of calcium ( 1, 2) . Values are increased when calcium intake is low and are reduced when calcium intake is high ( 1, 2) . 1,25 (OH)2D binds to its receptors in intestinal mucosa to enhance the transport of calcium (3) . Renal production of the metabolite is closely regulated by PTH (4, 5), calcium (6) , and phosphate (7, 8) ( 19, 20) and 1,25 (OH)2D (20) and two consecutive 24-h urine samples were obtained for measurement of calcium ( 17) and inorganic phosphate ( 18) . Urinary creatinine (21 ) was determined to ensure that urine collections were complete. Both the normal subjects and patients were readmitted for a second study after they had been given elemental calcium (calcium carbonate), 200 mg by mouth 3 times a day for I week (22) . The added calcium was continued during the second study. Statistical analyses were carried out with Student's paired and unpaired t tests.
Results
There were eight black and three white patients (Table I) (Table II) . Mean urinary phosphate was significantly higher in the normal subjects than in the patients. Increasing the calcium intake from 400 to 1,000 mg/d significantly increased mean urinary calcium by 44%, lowered mean urinary phosphate in the normal subjects, and significantly increased mean urinary calcium by 50% in the patients (Table II) . Mean serum calcium, serum Ca", and serum 25 (OH)D did not change in either the normal subjects or patients. Mean serum phosphate increased modestly in the normal subjects in response to the calcium, but did not change in the patients. The increased calcium intake significantly lowered mean serum 1,25 (OH)2D in the normal subjects but not in the patients (Table II, Figure 1 ).
Discussion
As noted already, we found that administration of modest doses of vitamin D to normocalcemic patients either with or without a history of hypercalcemia produced increases in serum 1,25 (OH)2D and abnormal calcium metabolism in each of them ( 13, 14) . The present findings showing failure of increased calcium intake to diminish serum 1,25(OH)2D in another group of normocalcemic patients with sarcoidosis who had no history of hypercalcemia provide evidence for abnormal vitamin D metabolism by a different means. In similar studies it was found that increases in calcium intake from 400 to 1,000 mg/d did not alter serum 1,25 (OH )2D in two patients with sarcoidosis in whom serum values were abnormally ele- 
